HC Wainwright Has Positive Estimate for DBVT FY2024 Earnings

DBV Technologies S.A. (NASDAQ:DBVT) – Analysts at HC Wainwright raised their FY2024 earnings per share (EPS) estimates for shares of DBV Technologies in a report released on Wednesday, October 23rd. HC Wainwright analyst A. Fein now anticipates that the company will post earnings per share of ($1.41) for the year, up from their previous forecast of ($1.43). HC Wainwright currently has a “Buy” rating and a $7.00 price objective on the stock. The consensus estimate for DBV Technologies’ current full-year earnings is ($1.43) per share. HC Wainwright also issued estimates for DBV Technologies’ FY2027 earnings at ($1.06) EPS and FY2028 earnings at ($0.50) EPS.

DBV Technologies (NASDAQ:DBVT) last announced its earnings results on Tuesday, July 30th. The company reported ($0.34) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.08). DBV Technologies had a negative net margin of 638.21% and a negative return on equity of 74.41%. The company had revenue of $1.16 million during the quarter, compared to analysts’ expectations of $1.42 million. During the same period in the prior year, the business earned ($0.26) earnings per share.

Other research analysts have also recently issued research reports about the company. StockNews.com initiated coverage on DBV Technologies in a research note on Monday, October 21st. They issued a “hold” rating on the stock. JMP Securities reiterated a “market outperform” rating and set a $5.00 price objective on shares of DBV Technologies in a research report on Tuesday, September 24th.

DBV Technologies Stock Performance

DBV Technologies stock opened at $0.87 on Friday. DBV Technologies has a fifty-two week low of $0.50 and a fifty-two week high of $2.28. The stock has a market cap of $83.61 million, a P/E ratio of -1.03 and a beta of 0.67. The firm’s fifty day moving average price is $0.77 and its 200-day moving average price is $0.96.

Institutional Trading of DBV Technologies

An institutional investor recently raised its position in DBV Technologies stock. Yiheng Capital Management L.P. lifted its stake in DBV Technologies S.A. (NASDAQ:DBVT) by 6.2% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 5,568,909 shares of the company’s stock after buying an additional 327,345 shares during the period. DBV Technologies makes up approximately 0.2% of Yiheng Capital Management L.P.’s holdings, making the stock its 15th largest holding. Yiheng Capital Management L.P. owned about 2.89% of DBV Technologies worth $4,172,000 as of its most recent SEC filing. Institutional investors own 71.74% of the company’s stock.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.